Applications that use HLA Typed Cells

The major histocompatibility complex (MHC) is a set of genes that code for cell surface proteins. These proteins are essential for the immune system to recognize foreign molecules. In humans, the MHC complex is called Human Leukocyte Antigen (HLA). HLA information has been and still is a critical factor for donor/recipient matching for organ and bone marrow transplants. Currently the need for HLA typed cells is driven by personalized cell therapies, cancer vaccine development and patient stratification for immune-oncology drug discovery.

HLA typing is used to genotype individuals at these loci. Historically this information was gathered serologically but with the advent of molecular technologies, more precise sequence information can be obtained with the use of next generation sequencing. HLA typed cells are critical in designing in vitro assays to identify on-and off-target cross -reactivities with proteins expressed on different tissues. Thus knowing the HLA genotype has become critical information for preclinical cell therapy and drug safety assessment studies.

Request information

HLA characterization from 50 different primary cell types from different tissues enables broad screening for cross reactivity testing
HLA Class I -A, B, C and Class II HLA-DPA1, -DPB1, -DQA1, DQB1, DRB1, available for cells obtained from major tissue types such as whole blood, leukopak, mobilized leukopak , bone marrow, lung, liver, skin, kidney, intestine, muscle, heart, cartilage, breast, brain, bone, eye.
High resolution HLA in for greater than 100 lots obtained by gold standard next generation sequencing methodologies (NGS) for class I and class II alleles

Detailed 2 field (6 digit) high resolution HLA data , (i.e the HLA prefix followed by gene name and 2 fields of the allele eg. HLA-A *02:01) for select lots and continuously expanding
Select the HLA type of your choice from multiple donors representing different genders and ethnicities across the population.
Multiple cell types from single donor tissue enables matched donor experiments Cord blood CD34+ cells can be HLA typed as a service through Cell Bio Services
Data will be included on the CoA.

Applications that use HLA typed cells

In the development of cancer immunotherapies, it is frequently critical to have primary cells from various tissues with a specific HLA genotype. The main areas for application of HLA typed primary cells are

For development of engineered TCRs to optimally select for HLA-TCR- peptide complex with the highest immunogenicity
For development of therapeutic antibodies known as TCR like antibodies targeting the peptide MHC (pMHC antibodies)
Cross reactivity testing across multiple tissue types for assessment of risk of development of cytokine storm or direct cytotoxicity
For studying the development of anti-drug antibodies (ADAs)
For development of neo-antigen peptide vaccines in cancer therapeutics

Thus, HLA information is a critical piece of information needed in the development of preclinical invitro assays in the immune oncology drug discovery field.

HLA typed primary cells

Multiple cell types from various tissues available with high resolution HLA information.

Cell types for HLA typing

Blood	PBMCs	T cells	B cells	Dendritic Cells	NK cells	CD14+ Monocytes	Leukopaks	Cord blood CD34+ cells
Lung	Bronchial Smooth Muscle	Human Lung MicroVascular Endothelial Cells	NHBE-Normal Human Bronchial Epithelial Cells for ALI	NHBE-Normal Human Bronchial Epithelial Cells with Retinoic Acid	NHBE- Normal Human Bronchial Epithelial Cells without Retinoic Acid	Normal Human Lung Fibroblasts	Human Small Airway Epithelial Cells
Skin	Human Epidermal Melanocytes	Human Dermal Microvascular Endothelial Cells	Human Dermal Fibroblasts	NHDF-Neo-Der Fibroblasts	Human Epidermal Keratinocytes	Human Epidermal Melanocytes
Heart	AoSMC-Aortic Smooth Muscle Cells	CASMC-Coronary Artery Smooth Muscle Cells	HAEC-Aortic Endothelial Cells	HCAEC-Coronary Art. Endothelial Cells	HMVEC-C Cardiac MV Endothelial Cells	HPAEC-Pulmon. Artery Endothelial cells	PASMC-Pulmon. Art. Smooth Muscle Cells
Bone Marrow	Mesenchymal Stem Cells	Bone marrow mononuclear cells	Hematopoietic Stem Cells (CD34+ cells)
Kidney	HRCE-Renal Cortical Epithelial Cells	HRE-Renal Epithelial Cells	RPTEC-Renal Proximal Tubule cells
Muscle	Human Skeletal Muscle Myoblasts	Human Skeletal Muscle Cells
Bone	NHOst-Normal Human Osteoblasts
Breast	HMEC-Mammary Epithelial Cells
Cartilage	NHAC-kn Articular Chondrocytes
Intestine	InMyoFib-Intestinal Myofibroblasts
Brain	NHA-Normal Human Astrocytes

Basics of HLA

MHC proteins supports self (our normal cells and tissues) vs non self-recognition (pathogens or modified self/cancer), in coordination with T Cell Receptor proteins(TCR) . T cells recognize foreign antigen/non- self peptide as a complex with MHC. Three classes of HLA exists in humans. MHC Class I is found on all nucleated cells in the body. Three major genes (A, B, C) comprise the Class I locus. MHC class I proteins displays peptides from within cells to T cells. Class II is found in addition to class I on antigen-presenting immune cells such as dendritic cells, B-cells, monocytes, macrophages. There are 6 main class II genes (DPA1, DPB1, DQA1, DQB1, DRA, DRB1). MHC class II displays peptides derived from exogenous antigens such as bacteria or viruses.. HLA-I molecules are both polygenic—being encoded by three genes (HLA-A, HLA-B, and HLA-C)—and highly polymorphic, with over 10,000 distinct alleles described thus far. The combination of multiple genes and alleles ensures enough diversification of HLA molecules to bind and present a wide range of peptides for T cell recognition and activation

Learn more

Development and manufacturing services

An extensive service offering that includes tailored process and analytical development, cGMP manufacturing, and regulatory services.

Learn more

Products and solutions

Our portfolio of research and manufacturing media, non-viral transfection technologies and primary cells, supports you through every step of the cell and gene therapy process.

Learn more

Therapy applications using hematopietic and stem cells

Immune responses to protein therapeutics are desired, such as when developing a vaccine

Learn more

References

Carey BS, Poulton KV, Poles A. Factors affecting HLA expression: A review. Int. J. Immunogenet. 2019 Oct;46(5):307-320

Fung MK and Benson K. Using HLA typing to support patients with cancer. Cancer Control 2015 Jan;22(1):79-86

Hirayama M and Nishimura Y.The present status and future prospects of peptide-based cancer vaccines.International Immunology, Volume 28, Issue 7, July 2016, Pages 319–328

Høydahl LS, Frick R, Sandlie I, Løset GÅ. Targeting the MHC Ligandome by Use of TCR-Like Antibodies. Antibodies 2019 May 9;8(2):32

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013 Aug 8; 122(6): 863–871

Mompó SM, González-Fernández A. Antigen-Specific Human Monoclonal Antibodies from Transgenic Mice. Methods Mol Biol.2019;1904:253-291

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013 Feb; 36(2): 133–151

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther. 2010 Apr; 18(4): 843–851

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Clinical Trial:Nature 2017 Jul 13;547(7662):217-221

Schultz HS, Reedtz-Runge SL, Bäckström BT, Lamberth K, Pedersen CR, Kvarnhammar AM; ABIRISK consortium. Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell: PBMC assay. PLoS One 2017 May 31;12(5)

Schumacher TN and Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015 Apr 3;348(6230):69-74

Sullivan A, Watkinson J, Waddington J, Park BK, Naisbitt DJ. Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions. Expert Opin Drug Metab Toxicol 2018 Mar;14(3):261-274

Timothy T Spear TT, Evavold BD, Baker BM, Nishimura MI. Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy. Cancer Immunol Immunother. 2019 Nov;68(11):1881-1889

Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J . 2018 Mar;32(3):1537-1549